- Home
- OPFI vs YMAB Comparison
OPFI vs YMAB Comparison
Compare OPFI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPFI
- YMAB
- Stock Information
- Founded
- OPFI 2009
- YMAB 2015
- Country
- OPFI United States
- YMAB United States
- Employees
- OPFI N/A
- YMAB N/A
- Industry
- OPFI Finance: Consumer Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- OPFI Finance
- YMAB Health Care
- Exchange
- OPFI Nasdaq
- YMAB Nasdaq
- Market Cap
- OPFI 205.2M
- YMAB 218.4M
- IPO Year
- OPFI N/A
- YMAB 2018
- Fundamental
- Price
- OPFI $11.60
- YMAB $4.04
- Analyst Decision
- OPFI Buy
- YMAB Buy
- Analyst Count
- OPFI 2
- YMAB 11
- Target Price
- OPFI $11.75
- YMAB $18.73
- AVG Volume (30 Days)
- OPFI 800.9K
- YMAB 204.4K
- Earning Date
- OPFI 05-07-2025
- YMAB 05-13-2025
- Dividend Yield
- OPFI 2.15%
- YMAB N/A
- EPS Growth
- OPFI N/A
- YMAB N/A
- EPS
- OPFI 0.36
- YMAB N/A
- Revenue
- OPFI $276,770,000.00
- YMAB $87,685,000.00
- Revenue This Year
- OPFI $112.50
- YMAB N/A
- Revenue Next Year
- OPFI $7.84
- YMAB $18.83
- P/E Ratio
- OPFI $32.25
- YMAB N/A
- Revenue Growth
- OPFI 22.23
- YMAB 3.38
- 52 Week Low
- OPFI $2.82
- YMAB $3.84
- 52 Week High
- OPFI $17.73
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- OPFI 71.65
- YMAB 42.87
- Support Level
- OPFI $9.43
- YMAB $4.02
- Resistance Level
- OPFI $10.07
- YMAB $4.60
- Average True Range (ATR)
- OPFI 0.50
- YMAB 0.32
- MACD
- OPFI 0.30
- YMAB -0.01
- Stochastic Oscillator
- OPFI 84.41
- YMAB 23.93
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.